サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1459803

サラセミア治療市場：世界の産業分析、規模、シェア、成長、動向、予測、2023-2031年

Thalassemia Treatment Market (Treatment Type: Blood Transfusion, Chelation Therapy, Bone Marrow Transplantation, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

出版日
ページ情報
英文 193 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
サラセミア治療市場：世界の産業分析、規模、シェア、成長、動向、予測、2023-2031年
出版日: 2024年02月07日
発行: Transparency Market Research
ページ情報: 英文 193 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

サラセミア治療市場- 調査範囲

TMR社の調査レポート「世界のサラセミア治療市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの世界のサラセミア治療市場の収益と予測を提供しています。また、2023年から2031年までの世界のサラセミア治療市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されました。1次調査では、主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、サラセミア治療市場を理解しました。

市場スナップショット
2022年の市場価値 7億9,180万米ドル
2031年の市場価値 15億米ドル
CAGR 7.3%

本レポートでは、世界のサラセミア治療市場の競合情勢について掘り下げています。世界のサラセミア治療市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイリングされています。企業概要、財務状況、最近の市場開拓、SWOTは、本レポートで紹介されている世界のサラセミア治療市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 市場概要
  • 市場力学
  • 世界市場分析と予測、2017年～2031年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要M&A
  • COVID-19パンデミックの産業への影響

第6章 世界市場分析と予測：治療タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：治療タイプ別、2017年～2031年
    • 輸血療法
    • キレーション療法
    • 骨髄移植
    • その他
  • 市場魅力度分析：治療タイプ別

第7章 世界市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017年～2031年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第8章 北米市場分析と予測

第9章 欧州市場分析と予測

第10章 アジア太平洋市場分析と予測

第11章 ラテンアメリカ市場分析と予測

第12章 中東・アフリカ市場分析と予測

第13章 競合情勢

  • 市場競合マトリックス（ティア別・企業規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Bluebird Bio, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Celgene Corporation
    • Takeda Pharmaceuticals Company Limited
    • Incyte Corporation
    • Sanofi
    • Bellicum Pharmaceuticals
    • GSK plc
図表

List of Tables

  • Table 01: Global Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 02: Global Thalassemia Treatment Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 03: North America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 04: North America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 05: Europe Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 06: Europe Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 07: Asia Pacific Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 08: Asia Pacific Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 09: Latin America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Latin America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 11: Middle East & Africa Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 12: Middle East & Africa Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2031

List of Figures

  • Figure 01: Global Thalassemia Treatment Market Size (US$ Mn) and Distribution (%), by Region, 2022-2031
  • Figure 02: Global Thalassemia Treatment Market Revenue (US$ Mn), by Treatment Type, 2022
  • Figure 03: Global Thalassemia Treatment Market Value Share, by Treatment Type, 2022
  • Figure 04: Global Thalassemia Treatment Market Value Share, by Region, 2022
  • Figure 05: Global Thalassemia Treatment Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 06: Global Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022-2031
  • Figure 07: Global Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 08: Global Thalassemia Treatment Market Value Share Analysis, by Region, 2022-2031
  • Figure 09: Global Thalassemia Treatment Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 10: North America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 11: North America Thalassemia Treatment Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 12: North America Thalassemia Treatment Market Value Share Analysis, by Country, 2022-2031
  • Figure 13: North America Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022-2031
  • Figure 14: North America Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 15: Europe Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 16: Europe Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 17: Europe Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 18: Europe Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022-2031
  • Figure 19: Europe Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 20: Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 21: Asia Pacific Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 22: Asia Pacific Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 23: Asia Pacific Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022-2031
  • Figure 24: Asia Pacific Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 25: Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 26: Latin America Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 27: Latin America Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 28: Latin America Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022-2031
  • Figure 29: Latin America Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 30: Middle East & Africa Thalassemia Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 31: Middle East & Africa Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 32: Middle East & Africa Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 33: Middle East & Africa Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022-2031
  • Figure 34: Middle East & Africa Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
目次
Product Code: TMRGL44462

Thalassemia Treatment Market - Scope of Report

TMR's report on the global thalassemia treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global thalassemia treatment market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global thalassemia treatment market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the thalassemia treatment market.

Market Snapshot
Market Value in 2022US$ 791.8 Mn
Market Value in 2031US$ 1.5 Bn
CAGR7.3%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global thalassemia treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global thalassemia treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global thalassemia treatment market.

The report delves into the competitive landscape of the global thalassemia treatment market. Key players operating in the global thalassemia treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global thalassemia treatment market profiled in this report.

Key Questions Answered in Global thalassemia treatment Market Report:

  • What is the sales/revenue generated by thalassemia treatment across all regions during the forecast period?
  • What are the opportunities in the global thalassemia treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Thalassemia Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global thalassemia treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global thalassemia treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global thalassemia treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Thalassemia Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Thalassemia Treatment Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Thalassemia Treatment Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 6.3.1. Blood Transfusion
    • 6.3.2. Chelation Therapy
    • 6.3.3. Bone Marrow Transplantation
    • 6.3.4. Others
  • 6.4. Market Attractiveness Analysis, by Treatment Type

7. Global Thalassemia Treatment Market Analysis and Forecast, by Region

  • 7.1. Key Findings
  • 7.2. Market Value Forecast, by Region, 2017-2031
    • 7.2.1. North America
    • 7.2.2. Europe
    • 7.2.3. Asia Pacific
    • 7.2.4. Latin America
    • 7.2.5. Middle East & Africa
  • 7.3. Market Attractiveness Analysis, by Region

8. North America Thalassemia Treatment Market Analysis and Forecast

  • 8.1. Introduction
  • 8.2. Key Findings
  • 8.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 8.3.1. Blood Transfusion
    • 8.3.2. Chelation Therapy
    • 8.3.3. Bone Marrow Transplantation
    • 8.3.4. Others
  • 8.4. Market Value Forecast, by Country, 2017-2031
    • 8.4.1. U.S.
    • 8.4.2. Canada
  • 8.5. Market Attractiveness Analysis
    • 8.5.1. By Treatment Type
    • 8.5.2. By Country

9. Europe Thalassemia Treatment Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 9.3.1. Blood Transfusion
    • 9.3.2. Chelation Therapy
    • 9.3.3. Bone Marrow Transplantation
    • 9.3.4. Others
  • 9.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 9.4.1. Germany
    • 9.4.2. U.K.
    • 9.4.3. France
    • 9.4.4. Italy
    • 9.4.5. Spain
    • 9.4.6. Rest of Europe
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Treatment Type
    • 9.5.2. By Country/Sub-region

10. Asia Pacific Thalassemia Treatment Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 10.3.1. Blood Transfusion
    • 10.3.2. Chelation Therapy
    • 10.3.3. Bone Marrow Transplantation
    • 10.3.4. Others
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. China
    • 10.4.2. Japan
    • 10.4.3. India
    • 10.4.4. Australia & New Zealand
    • 10.4.5. Rest of Asia Pacific
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Treatment Type
    • 10.5.2. By Country/Sub-region

11. Latin America Thalassemia Treatment Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 11.3.1. Blood Transfusion
    • 11.3.2. Chelation Therapy
    • 11.3.3. Bone Marrow Transplantation
    • 11.3.4. Others
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. Brazil
    • 11.4.2. Mexico
    • 11.4.3. Rest of Latin America
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Treatment Type
    • 11.5.2. By Country/Sub-region

12. Middle East & Africa Thalassemia Treatment Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 12.3.1. Blood Transfusion
    • 12.3.2. Chelation Therapy
    • 12.3.3. Bone Marrow Transplantation
    • 12.3.4. Others
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. GCC Countries
    • 12.4.2. South Africa
    • 12.4.3. Rest of Middle East & Africa
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Treatment Type
    • 12.5.2. By Country/Sub-region

13. Competition Landscape

  • 13.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 13.2. Market Share Analysis, by Company (2022)
  • 13.3. Company Profiles
    • 13.3.1. Bluebird Bio, Inc.
      • 13.3.1.1. Company Overview
      • 13.3.1.2. Product Portfolio
      • 13.3.1.3. SWOT Analysis
      • 13.3.1.4. Financial Overview
      • 13.3.1.5. Strategic Overview
    • 13.3.2. Merck & Co., Inc.
      • 13.3.2.1. Company Overview
      • 13.3.2.2. Product Portfolio
      • 13.3.2.3. SWOT Analysis
      • 13.3.2.4. Financial Overview
      • 13.3.2.5. Strategic Overview
    • 13.3.3. Novartis AG
      • 13.3.3.1. Company Overview
      • 13.3.3.2. Product Portfolio
      • 13.3.3.3. SWOT Analysis
      • 13.3.3.4. Financial Overview
      • 13.3.3.5. Strategic Overview
    • 13.3.4. Celgene Corporation
      • 13.3.4.1. Company Overview
      • 13.3.4.2. Product Portfolio
      • 13.3.4.3. SWOT Analysis
      • 13.3.4.4. Financial Overview
      • 13.3.4.5. Strategic Overview
    • 13.3.5. Takeda Pharmaceuticals Company Limited
      • 13.3.5.1. Company Overview
      • 13.3.5.2. Product Portfolio
      • 13.3.5.3. SWOT Analysis
      • 13.3.5.4. Financial Overview
      • 13.3.5.5. Strategic Overview
    • 13.3.6. Incyte Corporation
      • 13.3.6.1. Company Overview
      • 13.3.6.2. Product Portfolio
      • 13.3.6.3. SWOT Analysis
      • 13.3.6.4. Financial Overview
      • 13.3.6.5. Strategic Overview
    • 13.3.7. Sanofi
      • 13.3.7.1. Company Overview
      • 13.3.7.2. Product Portfolio
      • 13.3.7.3. SWOT Analysis
      • 13.3.7.4. Financial Overview
      • 13.3.7.5. Strategic Overview
    • 13.3.8. Bellicum Pharmaceuticals
      • 13.3.8.1. Company Overview
      • 13.3.8.2. Product Portfolio
      • 13.3.8.3. SWOT Analysis
      • 13.3.8.4. Financial Overview
      • 13.3.8.5. Strategic Overview
    • 13.3.9. GSK plc
      • 13.3.9.1. Company Overview
      • 13.3.9.2. Product Portfolio
      • 13.3.9.3. SWOT Analysis
      • 13.3.9.4. Financial Overview
      • 13.3.9.5. Strategic Overview